Hydrea (Hydroxyurea) - Summary

HYDREA SUMMARY

HYDREA^® (hydroxyurea capsules, USP) is an antineoplastic agent available for oral use as capsules providing 500 mg hydroxyurea.

HYDREA (hydroxyurea) is indicated for the following:

Significant tumor response to HYDREA (hydroxyurea capsules, USP) has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary.

Hydroxyurea used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

See all Hydrea indications & dosage >>

HYDREA NEWS HIGHLIGHTS

Published Studies Related to Hydrea (Hydroxyurea)

The effect of hydroxyurea in spinal muscular atrophy cells and patients. [2008.05.15]

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. [2007.12]

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. [2007.11]

Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. [2007.07.01]

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. [2007.03.15]

more >>

Clinical Trials Related to Hydrea (Hydroxyurea)

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG [Recruiting]

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG [Recruiting]

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) [Recruiting]

Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma [Recruiting]

Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease [Not yet recruiting]

more >>